Selma Atalay
Overview
Explore the profile of Selma Atalay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Schoot L, Atalay S, Otero M, Kievit W, van den Reek J, de Jong E
Br J Dermatol
. 2022 Jul;
187(6):1028-1030.
PMID: 35895852
No abstract available.
2.
Atalay S, Berends S, Groenewoud H, Mathot R, Njoo D, Mommers J, et al.
J Dermatolog Treat
. 2022 Feb;
33(5):2680-2684.
PMID: 35193441
Background: Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs....
3.
Atalay S, van der Schoot L, Vandermaesen L, van Vugt L, Eilander M, van den Reek J, et al.
Acta Derm Venereol
. 2021 Apr;
101(5):adv00463.
PMID: 33903920
Dose reduction of biologics for psoriasis could contribute to lower drug exposure. This study evaluated a one-step, tightly controlled, biologic dose reduction strategy in a prospective daily practice cohort. In...
4.
Atalay S, van den Reek J, Otero M, Njoo M, Mommers J, Ossenkoppele P, et al.
Acta Derm Venereol
. 2020 Nov;
100(19):adv00340.
PMID: 33196101
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR...
5.
Atalay S, van den Reek J, den Broeder A, van Vugt L, Otero M, Njoo M, et al.
JAMA Dermatol
. 2020 Feb;
156(4):393-400.
PMID: 32049319
Importance: Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible. Objective: To investigate whether dose reduction (DR) of biologics in...
6.
van den Bogaard E, van Geel M, van Vlijmen-Willems I, Jansen P, Peppelman M, van Erp P, et al.
Genet Med
. 2018 Nov;
21(7):1559-1567.
PMID: 30425301
Purpose: We aimed to assess the biological and clinical significance of the human cysteine protease inhibitor cystatin M/E, encoded by the CTS6 gene, in diseases of human hair and skin....
7.
Atalay S, van den Reek J, van Vugt L, Otero M, van de Kerkhof P, den Broeder A, et al.
BMC Dermatol
. 2017 May;
17(1):6.
PMID: 28482858
Background: Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that...
8.
Kerstens F, Turkstra F, Atalay S, van Vugt R, Swearingen C, Yazici Y
Clin Exp Rheumatol
. 2017 Apr;
35 Suppl 108(6):55-59.
PMID: 28406760
Objectives: To assess adherence to published guidelines for the treatment of Behçet's syndrome (BS) in two geographic areas. Methods: We extracted guideline statements from the 2008 EULAR recommendations. Adherence to...
9.
Bouman A, Atalay S, Ten Cate H, Ten Wolde M, Ten Cate-Hoek A
J Vasc Surg Venous Lymphat Disord
. 2016 Mar;
2(1):79-88.e3.
PMID: 26992975
Background: Post-thrombotic syndrome (PTS) is a serious condition that occurs in 20%-50% of patients following deep venous thrombosis (DVT). Biomarkers can be of use in further exploring the etiology as...
10.
van Doormaal F, Atalay S, Brouwer H, van der Velde E, Buller H, van Weert H
Ann Fam Med
. 2010 Jan;
8(1):47-50.
PMID: 20065278
Purpose: The association of spontaneous venous thromboembolism with occult malignancy is well established. Less clear is the incidence of subsequent cancer in patients with superficial thrombophlebitis. We wanted to determine...